Claims for Patent: 7,303,747

Summary for Patent: 7,303,747

Title:	Use of VEGF inhibitors for treatment of eye disorders
Abstract:	Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
Inventor(s):	Wiegand; Stanley J. (Croton-on-Hudson, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY), Fandl; James P. (LaGrangeville, NY), Daly; Thomas J. (New City, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	11/218,234
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,303,747
Patent Claims:	1. A therapeutic method for treating or ameliorating an eye disorder, comprising administering a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:6, wherein the eye disorder is associated with choroidal neovascularization, vascular leak, or retinal edema, and wherein administration is systemic. 2. The therapeutic method of claim 1, wherein the eye disorder is age related macular degeneration or diabetic retinopathy. 3. A method for the treatment of a human subject diagnosed with age-related macular degeneration, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human subject, the method comprising: (a) administering to the subject an initial dose of at least approximately 25-4000 micrograms VEGF inhibitor protein per eye; and (b) administering to the subject a plurality of subsequent doses of the VEGF inhibitor protein in an amount that is approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least two weeks, wherein the VEGF inhibitor is a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:6 and administration of the VEGF inhibitor is systemic. 4. The method of claim 3, wherein the initial dose is at least approximately 1000 micrograms of VEGF inhibitor protein. 5. The method of claim 4, wherein the subsequent doses are separated in time from each other by at least four weeks. 6. The method of claim 5, wherein the subsequent doses are separated in time from each other by at least 3 to 6 months.

Details for Patent 7,303,747

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	7,303,747	2039-02-26
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	7,303,747	2039-02-26

International Patent Family for US Patent 7,303,747

Country	Patent Number	Estimated Expiration
South Africa	200600157
South Africa	200110068
Yugoslavia	86901
World Intellectual Property Organization (WIPO)	2005000895